Shanu Modi
- Oncology top 0.2%
- HER2/EGFR in Cancer Research 137
- Cancer Treatment and Pharmacology 78
- Peptidase Inhibition and Analysis 18
-
- Monoclonal and Polyclonal Antibodies Research 55
- Radiopharmaceutical Chemistry and Applications 23
- Cancer Research top 2%
- Breast Cancer Treatment Studies 40
-
- Advanced Breast Cancer Therapies 63
- Lung Cancer Treatments and Mutations 23
- Genetics top 2%
Shanu Modi
221 papers receiving 8.5k citations
Hit Papers
Peers
Comparison fields: 5 of 125
- Oncology 5.8k
- Radiology, Nuclear Medicine and Imaging 2.9k
- Cancer Research 1.1k
- Pulmonary and Respiratory Medicine 2.0k
- Genetics 549
Countries citing papers authored by Shanu Modi
This map shows the geographic impact of Shanu Modi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Shanu Modi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Shanu Modi more than expected).
Fields of papers citing papers by Shanu Modi
This network shows the impact of papers produced by Shanu Modi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Shanu Modi. The network helps show where Shanu Modi may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Shanu Modi, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2025 | 1 | |
| 2 | 2025 | 3 | |
| 3 | 2024 | 0 | |
| 4 | 2024 | 2 | |
| 5 | 2024 | 1 | |
| 6 | 2024 | 1 | |
| 7 | 2024 | 13 | |
| 8 | 2023 | 28 | |
| 9 | 2023 | 8 | |
| 10 | 2023 | 2 | |
| 11 | 2022 | 25 | |
| 12 | 2021 | 26 | |
| 13 | 2020 | 15 | |
| 14 | Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive breast cancer previously treated with trastuzumab emtansine: a dose-expansion, phase 1 studybreakdown → | 2019 | 258 |
| 15 | 2019 | 162 | |
| 16 | 2014 | 258 | |
| 17 | 2014 | 134 | |
| 18 | 2013 | 57 | |
| 19 | 2012 | 49 | |
| 20 | 2011 | 328 |
About Shanu Modi
Shanu Modi is a scholar working on Oncology, Cancer Research and Radiology, Nuclear Medicine and Imaging, having authored 233 papers that have together received 8.6k indexed citations. Recurring topics across this work include HER2/EGFR in Cancer Research (137 papers), Cancer Treatment and Pharmacology (78 papers), Advanced Breast Cancer Therapies (63 papers), Monoclonal and Polyclonal Antibodies Research (55 papers), Breast Cancer Treatment Studies (40 papers), Radiopharmaceutical Chemistry and Applications (23 papers), Lung Cancer Treatments and Mutations (23 papers) and Peptidase Inhibition and Analysis (18 papers). The work is most often cited by research in Oncology (5.8k citations), Radiology, Nuclear Medicine and Imaging (2.9k citations) and Cancer Research (1.1k citations). Shanu Modi has collaborated with scholars based in United States, Japan and Spain. Frequent co-authors include Sarat Chandarlapaty, Joshua Z. Drago, Ian E. Krop, Clifford A. Hudis, Komal Jhaveri, Larry Norton, Gabriela Chiosis, Tony Taldone, Hiroji Iwata and Shunji Takahashi. Their work appears in journals such as Journal of Clinical Oncology, Cancer Research, Annals of Oncology, Clinical Breast Cancer and Clinical Cancer Research.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.